Review the latest data and expert guidance on PARP inhibitors to enhance your treatment of ovarian cancer. This comprehensive CME/CE/CPE-certified program features decision support tools, focused commentaries, an expert analysis module, and a downloadable slideset.
Have you fully integrated the PARP inhibitors—olaparib, niraparib, and rucaparib—into your clinical practice in ovarian cancer? In this commentary, I discuss the importance of PARP inhibitors in ovarian cancer treatment and review considerations guiding their use.
Are you aware of the latest data on PARP inhibitors in ovarian cancer? In this commentary, I will discuss 3 key studies on olaparib, rucaparib, and niraparib in platinum-sensitive recurrent ovarian cancer that were presented at ASCO 2019.
Read this expert commentary to gain practical clinical insights on managing adverse events associated with PARP inhibitors to maximize clinical benefit for patients with ovarian cancer.
Gain expert insights from Kathleen Moore, MD, on key findings from the QUADRA trial that led to FDA label expansion of niraparib in ovarian cancer.
Use this Interactive Decision Support Tool to see management recommendations in the frontline and second-line settings for advanced-stage ovarian cancer from 5 renowned experts.
Robert L. Colman, MD; Virginia Bayer, BSN, RN, OCN; and Laura Alwan, PharmD, BCOP, review patient cases and supporting clinical data to provide insights and guidance on the use of PARP inhibitors in ovarian cancer.
Download these slides to review expert insights on optimizing the use of PARP inhibitors in ovarian cancer.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.